BridgeBio Pharma Inc (BBIO) Stock Analysis
Verdict: HOLD
Breakout momentum fueled by competitor failures in ATTR-CM offset by severe balance sheet debt and aggressive insider selling.
Investment score: 62/100
Analysis as of
Is BridgeBio Pharma Inc stock worth reviewing? AI model thesis
BBIO is a high-growth biotech play currently benefiting from competitor setbacks, yet burdened by significant debt and insider selling.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 50/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 88/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
BridgeBio Pharma Inc opportunities and risks
What speaks for BBIO
- ATTR-CM Market Leadership Consolidation
What speaks against BBIO
- Severe Debt Burden and Cash Burn
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| BBIO | n/a | 30.5x | n/a | 93.8% | -125.2% | -2.6% |
| INSM | n/a | 31.3x | n/a | 81.6% | -144.4% | -3.7% |
| INCY | 16.2x | 4.4x | 10.8x | 92.5% | 26.7% | 6.1% |
| UTHR | 18.9x | 7.4x | 13.1x | 86.6% | 40.6% | 4.3% |
| NBIX | 26.9x | 5.9x | 19.1x | 98.2% | 21.6% | 4.6% |
| EXEL | 18.3x | 6.0x | 14.1x | 96.4% | 35.1% | 6.4% |
| Peer median | 18.3x | 6.0x | 13.1x | 92.5% | 26.7% | 4.6% |
Frequently asked questions about BridgeBio Pharma Inc (BBIO)
Is BBIO stock a good investment?
The cached TradeMates AI model rates BridgeBio Pharma Inc as HOLD with an investment score of 62/100. BBIO is a high-growth biotech play currently benefiting from competitor setbacks, yet burdened by significant debt and insider selling. This is algorithmic model output, not personal investment advice.
Is BBIO stock a buy?
The TradeMates model verdict for BBIO is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.